Puma Biotechnology (PBYI) Change in Receivables (2013 - 2026)

Puma Biotechnology has reported Change in Receivables for 12 years, with the latest figure at -$27.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 312.39% year-over-year to -$27.3 million; the trailing twelve-month figure through Mar 2026 stood at $582000.0 (up 238.37% YoY), and the FY2025 full-year result was $21.3 million, up 230.2% from the prior year.
• Change in Receivables for Q1 2026 stood at -$27.3 million, down from $20.1 million in the prior quarter.
• The five-year high for Change in Receivables was $26.5 million in Q3 2024, with the low at -$27.3 million in Q1 2026.
• Historically, Change in Receivables has averaged -$364529.4 across 5 years, with a median of $376000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Receivables plunged 992.2% — and 2024, when it surged 1243.78%.
• Puma Biotechnology's Change in Receivables stood at $12.3 million in 2022, then soared by 56.09% to $19.2 million in 2023, then tumbled by 219.76% to -$23.0 million in 2024, then surged by 187.23% to $20.1 million in 2025, then plunged by 236.02% to -$27.3 million in 2026.
• The last three Change in Receivables figures came in at -$27.3 million (Q1 2026), $20.1 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.